AddedRisk Factors
the FDA in the United States and, if manufactured outside of the United States, both the FDA and non-U.S. regulatory agencies, such as the MHRA and the EMA. With respect to a product, to the extent that operational standards set by such agencies are not adhered to, manufacturing facilities may be closed or production interrupted until such time as any deficiencies noted by such agencies are remedied. Any such closure or interruption may interrupt, for an indefinite period of time, the manufacture and distribution of a product and therefore the cash flows from the related biopharmaceutical asset may be significantly less than expected.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
In addition, manufacturers of a product may rely on third parties for selected aspects of product development, such as packaging or to supply bulk raw material used in the manufacture of such product. In the United States, the FDA requires that all suppliers of pharmaceutical bulk materials and all manufacturers of pharmaceuticals for sale in or from the United States adhere to the FDA’s current “Good Manufacturing Practice” regulations and guidelines and similar requirements that exist in jurisdictions outside the United States. Marketers of biopharmaceutical products generally rely on a small number of key, highly specialized suppliers, manufacturers and packagers. Any interruptions, however minimal, in the operation of these manufacturing and packaging facilities could adversely affect production and product sales and therefore adversely affect our business, financial condition or results of operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
In addition, our collaboration partners may develop products, either alone or with others, that compete with the types of products they are developing with us (or that we are developing on our own). This would result in increased competition for our
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
We may undertake strategic acquisitions of operating biopharmaceutical companies or acquire securities of biopharmaceutical companies. Our failure to realize the expected benefits of such acquisitions could adversely affect our business, financial condition or results of operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedRisk Factors
•Risks we may face if we do not consummate a strategic transaction involving our Pelthos business and continue to operate Pelthos on a go-forward basis.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
the biotechnology industry, the volatility of that industry can affect us indirectly as well as directly. The same factors that affect us directly also can adversely affect us indirectly by affecting the ability of our partners and others with whom we do business to meet their obligations to us and reduce our ability to realize the value of the consideration provided to us by these other companies in connection with their licensing of our products.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
patents and patent applications or licensed patents and patent applications has been found, which could be used by a third party to challenge their validity, or prevent a patent from issuing from a pending patent application.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
The Pelthos business may suffer from uncertain business operations if we do not consummate a transaction or enter into commercial partnerships involving Pelthos.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Consistent with our business model, we are engaging with potential commercial partners to maximize the value for our stockholders of the assets we acquired through the Novan acquisition that are held by our Pelthos business (including ZELSUVMI and other assets that may be developed using the NITRICIL technology platform) through a licensing or other strategic transaction involving Pelthos. If we do not consummate a transaction or enter into commercial partnerships, we will continue to be exposed to uncertainties with respect to the continued operations of the Pelthos business. Such uncertainties may affect our results of operations similarly to those faced by our Captisol business as described above under “Risks Related to Our Business Operations and Reliance on Third Parties.”
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
If we are unable to remediate any material weakness in our internal control over financial reporting or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately and timely report our financial results, in which case our business may be harmed, investors may lose confidence in the accuracy and completeness of our financial reports, and the price of our common stock may decline.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our management is responsible for establishing and maintaining adequate internal control over financial reporting and for evaluating and reporting on the effectiveness of our system of internal control, including monitoring corrective actions. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with GAAP. We are required to furnish annually a report by management of its assessment of the effectiveness of our internal control over
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
financial reporting as of the end of our most recent fiscal year. In addition, our independent registered public accounting firm is required to provide a related attestation report on our internal control over financial reporting.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
In connection with our 2024 year-end assessment of internal control over financial reporting, we determined that the previously identified material weakness related to the ineffective process-level control activities in the business combination processes were remediated as of December 31, 2024. For further discussion of the material weakness identified and our remedial efforts, see Item 9A. Controls and Procedures.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
If we are unable to monitor and remediate successfully any future material weakness or other deficiencies in our internal control over financial reporting: the accuracy and timing of our financial reporting may be adversely affected; our liquidity, our access to capital markets, the perceptions of our creditworthiness, and our ability to complete acquisitions may be adversely affected; we may be unable to maintain compliance with applicable securities laws, Nasdaq listing requirements, and the covenants under our debt instruments regarding the timely filing of periodic reports; we may be subject to regulatory investigations and penalties; and investors may lose confidence in our financial reporting. If any such event or circumstance were to occur, our stock price could decline and our business, financial condition and results of operations could be materially adversely affected.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
we fail to deliver Captisol timely, interruption or delays to discovery and development pipelines and difficulties launching or commercializing products, including due to reduced access to doctors as a result of social distancing protocols.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedRisk Factors
If For example, we fail to comply with applicable laws and regulations we could be subject to penalties or sanctions, including criminal penalties if we knowingly may obtain or disclose individually identifiable health information from a covered entity in a manner third parties (including research institutions from which we obtain clinical trial data) that is not authorized or permitted by are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder (collectively, “HIPAA”) or applicable state laws.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Even if we do obtain orphan drug designations and are the first to obtain marketing approval of our product candidates for the applicable indications, we will not be able to rely on these designations to exclude other companies from manufacturing or selling biological products using the same principal molecular structural features for the same indication beyond these timeframes.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Setbacks for the products could include problems with shipping, distribution, manufacturing, product safety, marketing, government regulation or reimbursement, licenses and approvals, intellectual property rights, including failure by any of the foregoing partners to enforce their respective intellectual property rights, competition with existing or new products and physician or patient acceptance of the products, as well as higher than expected total rebates, returns, discounts, or unfavorable exchange rates.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although we believe that we and our partners have adjusted our business practices to the impacts of the COVID-19 pandemic, in the future, we may experience similar pandemics or epidemic diseases that could severely impact our business, drug manufacturing and supply chain, nonclinical activities and clinical trials and our partners’ business may be impacted in similar ways, including due to delays or difficulties in enrolling patients in clinical trials, diversion of healthcare resources away from the conduct of clinical trials, interruption of, or delays in receiving, supplies of Captisol or other product or product candidates from contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems, which may result in cancellations of Captisol orders or refunds if we fail to deliver Captisol timely, interruption or delays to discovery and development pipelines and difficulties launching or commercializing products, including due to reduced access to doctors as a result of social distancing protocols.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we fail to comply with any such laws, rules or regulations, we may face government investigations and/or enforcement actions, fines, civil or criminal penalties, private litigation or adverse publicity that could adversely affect our business, financial condition and results of operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
It may be necessary for us to pursue litigation or adversarial proceedings before the patent office in order to enforce our patent and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
The DPF EU-US Data Privacy Framework (“DPF”) also introduced a transfer mechanism for transfers between the E.U. and U.S. with a new redress mechanism for E.U. citizens which addresses a key concern in the previous CJEU Court of Justice of the European Union judgments and may mean transfers under standard contractual clauses are less likely to be challenged in future.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
If a prolonged government shutdown occurs, or if there are other significant changes in funding, it could significantly impact the ability of the FDA to provide feedback on clinical trials and development programs, to meet with sponsors and to otherwise timely review and process our regulatory submissions, which could have a material adverse effect on our business.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
It also created The CCPA is enforced by the California Privacy Protection Agency, a new California data protection agency authorized authority, which has the power to issue substantive regulations and could result in increased privacy and information security enforcement.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
The FDA or comparable foreign regulatory authorities, as the case may be, may also require us or our partners to conduct additional preclinical nonclinical studies or clinical trials for our product candidates either prior to or post-approval, or may object to elements of clinical development programs.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
While we do not believe that we have experienced any significant system failures, accidents or security breaches, if If such an event events were to occur and cause interruptions in our or our critical third parties’ operations, it could lead to the loss of trade secrets or other intellectual property, as well as the public exposure of personal information of our employees and others, and could result in a material disruption of our clinical and commercialization activities and business operations, in addition to possibly requiring substantial expenditures to remedy.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
The diversion of our management's management’s attention and any delay or difficulties encountered in connection with any future acquisitions we may consummate could result in the disruption of our ongoing on-going business or inconsistencies in standards and controls that could negatively affect our ability to maintain third-party relationships. operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
(1) Our royalty rate on Ohtuvayre is 3%, of which 2% is recognized in revenue from intangible royalty assets and the remaining 1% is accounted for as financial royalty asset.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The gain from change in fair value of equity method investments and other investments was $90.7 million for 2025, attributable to the fair value changes of the shares of Pelthos common stock and Pelthos Series A convertible preferred stock that we acquired in connection with the Pelthos Transaction. For additional information, see Note 2, Pelthos Transaction. The loss from change in fair value of equity method investments and other investments was $34.6 million for 2024, attributable to the fair value adjustment of $25.8 million to Primrose Bio securities investment, the $5.8 million impairment to Primrose Bio equity method investment, and the $3.0 million impairment loss related to Neuritek warrants.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
On August 14, 2025, we issued the 2030 Notes. The $460 million aggregate principal balance of the 2030 Notes includes the purchase of an additional $60 million aggregate principal amount of the 2030 Notes by the initial purchasers pursuant to the full exercise of their overallotment option. The net proceeds from the 2030 Notes offering were approximately $445.1 million, after deducting the initial purchasers’ discounts and commissions and the debt issuance costs incurred by Ligand. Refer to Note 9, Debt, for more information on the 2030 Notes.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In connection with the offering of the 2030 Notes, on August 11, 2025, we entered into the second amendment to the Credit Agreement, to permit, among other things, certain cash settlement payments on the 2030 Notes, subject to customary conditions set forth therein. On September 12, 2025, we entered into the third amendment to the Credit Agreement to, among other things, extend the maturity date to September 12, 2028 and modify the minimum consolidated EBITDA (as defined in the Credit Agreement) covenant to require us to maintain not less than $55 million of consolidated EBITDA (as defined in the Credit Agreement) for the trailing four-quarter period ended September 30, 2025 and each trailing four-quarter period ending thereafter.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In 2025, we generated cash from operations primarily from revenue and operating income which was partially offset by our investments in Castle Creek and Orchestra R&D funding arrangements, and cash operating expenses. We used cash in investing activities primarily for purchases of short-term and other investments, financial royalty assets, and derivative assets, as well as cash outflow on deconsolidation of LNHC, Inc., partially offset by cash proceeds from sale and maturity of short-term investments, and cash proceeds from financial royalty assets. We generated cash from financing activities primarily due to net proceeds from the issuance of the 2030 Notes and related transactions (i.e., purchase of hedge, issuance of warrants, and repurchase of shares), stock options exercises and ESPP, as well as proceeds from Pelthos investors bridge loans. Refer to Note 2, Pelthos Transaction, for more information on the Pelthos Transaction, and Note 9, Debt, for more information on the 2030 Notes.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedMD&A
On March 23, 2022, we entered into (i) an Agreement and Plan of Merger (the “OmniAb Merger Agreement”), among Ligand, OmniAb, Avista Public Acquisition Corp. II, a Cayman Islands exempted company (“APAC”), and Orwell Merger Sub, Inc., a wholly owned subsidiary of APAC (“Merger Sub”), and (ii) a Separation and Distribution Agreement (the “OmniAb Separation and Distribution Agreement”), among Ligand, OmniAb and APAC. Prior to the effective time of the OmniAb Merger (defined below), APAC migrated to and domesticated as a Delaware corporation (“New OmniAb”) in accordance with the terms and conditions of the OmniAb Merger Agreement. Pursuant to the OmniAb Separation and Distribution Agreement, we, prior to the effective time of the OmniAb Merger (i) transferred our then-antibody discovery business (the “OmniAb Business”), including certain of our related subsidiaries, to OmniAb (the “OmniAb Separation”) and (ii) in connection therewith, distributed 100% of OmniAb’s common stock held by Ligand to Ligand stockholders (the “OmniAb Distribution”). We also contributed to OmniAb cash and certain specific assets and liabilities constituting the OmniAb Business. Following the OmniAb Separation and the OmniAb Distribution, on November 1, 2022, in accordance with and subject to the terms and conditions of the OmniAb Merger Agreement, Merger Sub merged with and into OmniAb, with OmniAb continuing as the surviving company and wholly-owned subsidiary of New OmniAb on and after the effective time of the merger (the “OmniAb Merger”). In addition, New OmniAb changed its corporate name to “OmniAb, Inc.” concurrently upon the effectiveness of the OmniAb Merger.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
After the OmniAb Distribution, we do not beneficially own any shares of common stock in OmniAb and no longer consolidate OmniAb into our financial results for periods ending after October 31, 2022. As a result, OmniAb's historical financial results through the OmniAb Separation are reflected in our consolidated financial statements as discontinued operations.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Revenue from intangible royalty assets is a function of our partners' product sales and the applicable royalty rate. Kyprolis royalty rate is under a tiered royalty rate structure with the highest being 3%. Evomela has a contractually fixed royalty rate of 20%. Teriparatide injection has a tiered gross profit share between 25% and 40% on sales that have been adjusted for certain deductible items as defined in the respective license agreement. The Rylaze and Vaxnuevance royalty rates are in the low single digits. Filspari has a fixed royalty rate of 9%.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
(Dollars in thousands) 2024 2023 Change % Change Cost of Captisol $ 11,074 $ 10,512 $ 562 5% Amortization of intangibles 32,959 33,654 (695) (2)% Research and development 21,425 24,537 (3,112) (13)% General and administrative 78,654 52,790 25,864 49% Financial royalty assets impairment 30,572 — 30,572 n/a Fair value adjustment to partner program derivatives 15,055 — 15,055 n/a Total operating costs and expenses $ 189,739 $ 121,493 $ 68,246 56%
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Cost of Captisol increased year over year in 2024 primarily due to higher sales of Captisol during 2024 compared to 2023.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
General and administrative expenses increased by $25.9 million in 2024 compared to 2023, with the increase primarily driven by higher stock-based compensation expenses for investments made in building out our business development and investment team. Additionally, a one-time, non-cash stock award modification expense related to the departure of Ligand's former Chief Operating Officer and costs associated with incubating the Pelthos Therapeutics business contributed to the increase.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
The gain on sale of Pelican in the amount of $2.1 million for 2023 represents the excess of the fair value of 1) our investment in Primrose Bio and other economic rights; 2) the carrying amount of Pelican business assets and liabilities together with allocated goodwill as of September 18, 2023, the date of sale; and 3) $15 million consideration paid.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
(Dollars in thousands) 2024 2023 Change % Change Income before income tax expense (benefit) from continuing operations $ 2,518 $ 63,660 $ (61,142) (96)% Income expense (6,550) (9,841) 3,291 (33)% Net income (loss) from continuing operations $ (4,032) $ 53,819 $ (57,851) (107)% Effective Tax Rate 260 % 15 %
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
certain securities which are classified as short-term investments that we received as a result of a milestone and an upfront license payment as well as 1.0 million shares of common stock in Viking.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Valuation of Partnered Programs Derivative Assets Acquired in Agenus Transaction
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Partnered Programs acquired in the transaction with Agenus are accounted for as derivative assets under ASC 815, Derivatives and Hedging, and were recorded at fair value at acquisition. These derivative assets are marked to fair value at each subsequent reporting period. To determine the fair value of the derivative assets, the Company applied a discounted cash flow model using observable and unobservable market data for inputs, including the estimated amount and timing of the expected cash flows and the probability of success of underlying clinical programs which considers the level of risk appropriate for a respective program stage.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedMD&A
Interest expense in 2023 consists primarily of 1) the 0.75% coupon cash interest expense in addition to the non-cash accretion of discount (including the amortization of debt issuance costs) on our 2023 Notes. 2030 Notes issued in August 2025, and 2) interest accrued related to a royalty and milestone payments purchase agreement entered into by Novan, Inc. in 2019, assumed by Ligand as part of the Novan acquisition in September 2023, and deconsolidated on July 1, 2025.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
In addition, the increase was driven by changes in the fair value of our ownership in Viking common stock (an unrealized gain of $9.0 million in 2024 compared to an unrealized gain of $2.6 million in 2023) and 2024, we recorded a $7.1 million net gain on the arrangements we executed and exercised in 2024 to hedge against the fluctuation in Viking's Viking’s share price.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
During the year, we We used cash in financing activities primarily for financing activities, including the repayment of the remaining $76.9 million principal amount upon maturity of the 2023 Notes upon maturity, partially offset by net proceeds from stock options exercises and $0.3 million accrued interest in cash. ESPP.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Total revenue and other income increased by $35.8 $101.0 million, or 27%, 60%, to $268.1 million in 2025 compared to $167.1 million in 2024 compared to $131.3 million in 2023 primarily due to the $23.8 $52.2 million increase in royalties. royalties and $39.4 million increase in contract revenue and income.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Captisol sales increased by $2.5 $9.3 million to $40.2 million in 2025 compared to $30.9 million in 2024 compared to $28.4 million in 2023. 2024.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Fair value adjustment to partner program derivatives was The $15.1 million for gain recognized in 2024 primarily was due to certain Agenus partners discontinuing development of their partnered programs.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Other non-operating expense, net, primarily consists of mark-to-market adjustments on derivatives (other than Viking Share Collar and Put and the partner program derivatives) and derivatives), mark-to-market adjustments on CVRs and absorbed losses on for equity method investments. investment in Primrose Bio.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
As of December 31, 2024, 2025, we had $3.7 $3.2 million in fair value of contingent consideration liabilities associated with the acquisitions related to our business combinations to be settled in future periods.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Financial royalty asset The 2024 impairment was of $30.6 million for 2024 was primarily due to Takeda's Takeda’s decision to discontinue the soticlestat program.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Interest income consists primarily of interest earned on our short-term investments and remained relatively steady in 2024 compared to 2023. investments.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Our effective tax rate for 2025 and 2024 was 22% and 2023 was 260% and 15%, 260%, respectively.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in royalties in 2024 2025 was primarily due to income from Qarziba financial royalty asset acquired in the third quarter of 2024 and an increase in sales of Travere Therapeutics’ Filspari. Filspari, Ohtuvayre and Capvaxive.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new